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Hemodialysis leukopenia and complement function with different dia-
lyzers. The relationship between leukopenia and the complement sys-
tem during hemodialysis was re-examined by studying not only the in
vivo effects of four different dialyzer membranes (cellulose hydrate,
cuprophan, cellulose acetate, and polyacrilonitrile) on leukocyte counts
and complement levels, but especially by investigating the effects of
these membranes on complement function in vitro. Whereas from in
vivo studies no definite conclusions could be drawn, in vitro investiga-
tions provided clear-cut information. When more sophisticated techni-
cal approaches were undertaken, it became evident that hemodialysis
leukopenia has to be thought of in terms of chemotactic factor genera-
tion. In fact, a strict correlation was demonstrated between the degree
of leukopenia induced by the dialyzers tested and the ability of the
relative membrane to generate chemotactic activity in vitro. Moreover,
the previously observed ability of polyacrilonitrile membrane to induce
a decrement in complement function was due to the ability of polyacri-
lonitrile to adsorb complement activity and did not correspond to
effective complement consumption. This finding explained why polyac-
rilonitrile dialysis is not accompanied by a decrease in circulating
granulocytes. Taken together, our data strongly point to a pivotal role
of complement system in the pathogenesis of hemodialysis leukopenia.
Leucopénie de l'hémodialyse et fonction du complement avec différents
dialyseurs. La relation entre la leucopénie et le système complémentaire
pendant l'hemodialyse a ete réexaminée en étudiant non seulement les
effets in vivo de quatre membranes de dialyse différentes (hydrate de
cellulose, cuprophan, acetate de cellulose, et polyacrilonitrile) sur les
numerations leucocytaires et les niveaux du complement, mais surtout
en étudiant les effets de ces membranes sur Ia fonction complémentaire
in vitro. Alors que des etudes in viva aucune conclusion definitive ne
pouvait être tirée, les etudes in vitro ont apporté des informations
précises. Quand des approches techniques plus sophistiquees ont été
utilisées, il est apparu evident que Ia leucopenie de l'hemodialyse doit
être pensée en termes de génération de facteurs chimiotactiques. De
fait, une correlation stricte a été démontrée entre le degre de leucopénie
induite par Ic dialyseur testé et Ia capacite de Ia membrane a generer
une activité chimiotactique in vitro. En outre, Ia capacitC prCalablement
observée de Ia membrane en polyacrilonitrile d'induire une diminution
de Ia fonction complémentaire était doe ala capacité du polyacrilonitrile
d'absorber l'activité comptémentaire, et ne correspondait pas a une
consommation effective du complement. Ce résultat a explique pour-
quoi Ia dialyse au polyacrilonitrile n'était pas accompagnee par une
diminution des granulocytes circulants. Prises dans leur ensemble, nos
données mettent fortement l'accent stir un rôle-cle du système complé-
mentaire dans Ia pathogénie de leucopCnie de l'hémodialyse.
decrease of arterial P02 [5, 6]. The phenomenon specifically
involves granulocytes and monocytes, cells sharing plasma
membrane reactivity toward activated complement compo-
nents. Many data, obtained both in experimental models [7] and
humans [8—11] strongly support the hypothesis that comple-
ment activation plays a pivotal role in the pathogenesis of
hemodialysis-induced leukopenia through the release of chemo-
tactic factors, as C5a, C567, and perhaps C3a [12—14].
Recently, however, some doubt has been cast on the central
role of complement activation in the dialysis-mediated leukope-
nia and hypoxemia. Main criticism of this hypothesis came from
the finding that polyacrilonitrile membranes caused a reduction
in complement function without inducing significant neutrope-
nia, whereas polycarbonate dialyzers provoked a sizeable drop
in leukocyte counts without detectable complement depletion
[15, 16]. Moreover, when individual patients are considered, no
relationship is found between the intensity of complement
depletion and induced neutropenia [17]. Finally, leukopenia and
hypoxemia seem to be unrelated effects of hemodialysis, the
latter occurring with dialyzers that do not cause any significant
change in leukocyte counts [18].
The aim of the present study is to re-assess the relationship
between complement system and neutropenia during hemodial-
ysis. For this purpose, the behavior of four different dialyzer
membranes with regard to in vivo and in vitro effects on
complement function will be examined by using sensitive
techniques for the detection of chemotactic factors putatively
responsible for pulmonary leukocyte trapping [19, 20].
Methods
Patients. Four groups of eight patients undergoing routine
hemodialysis for endstage renal failure were studied by using
four different types of dialyzers. None of them had clinical
evidence of infection or was taking drugs known to affect
leukocyte counts or complement function. Age and sex distri-
bution was comparable between groups. Dialyzer membranes
used were cellulose hydrate (Sifra Secon 104, Ravizza, Italy),
It has long been known that early hemodialysis is accompa-
nied by a profound, transient leukopenia [1, 21. This leukopciiia
is due to a selective cell sequestration in the pulmonary
microvasculature [3, 41 and is accompanied by a progressive
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cuprophan (UF 3.2 AB Gambro, Lund, Sweden), cellulose
acetate (CDAK 3500, Cordis Dow Corp., Miami, Florida), and
polyacrilonitrile (Hospal RP 610 Dasco, Bologna, Italy). The
dialyzer membranes had not been used previously and were
primed with saline.
Blood samples were collected from the afferent line, just
proximal to the point of heparin infusion, before (time 0) and at
15 mm and 1 and 4 hr of dialysis. Leukocyte counts were
performed in duplicate using an automatic cell counter (Coulter
Harpenden, Herts, England). Leukocyte differential counts
were determined by standard methods. Blood gas determina-
tions were obtained with commercially available instruments.
Aliquots of plasma for complement studies were stored in liquid
nitrogen and thawed only once for testing. Normal plasma or
serum samples were collected from laboratory personnel.
Complement assays
CH 50. Classical pathway hemolytic activity was determined
by the method of Kabat and Mayer [211. To obviate as far as
possible interassay variability, plasma samples from each pa-
tient were always tested all at once in the same experiment, and
patients undergoing dialysis with different membranes were
grouped in a single test. Results were expressed in CH 50 units
(50% hemolysis point), and the percentage of pre-dialysis
values was calculated. With regard to the intra-test variability,
the coefficient of variation (SD x 100/mean) was evaluated by
the replicate testing of a sample in the same experiment, and
confidence limits were set at twice the coefficient of variation
(6%). For individual patients, any variation from the basal value
exceeding 6% was considered significant (P < 0.05).
AP 50. Alternative pathway hemolytic activity was deter-
mined by the method of Platts-Mills and Ishizaka [22]. Experi-
ments were planned as described for the CH 50 test, and the
percentage of pre-dialysis values was calculated from the
results expressed in AP 50 U. For each patient, any variation
from the basal value exceeding twice the coefficient of variation
(6%) was considered significant.
Factor B assay. Functional molecule titration was used for
the evaluation of factor B (Bf) in the serum. As a finishing
reagent containing all the components other than the one under
test, serum heated for 20 mm at 50°C (R-Bf) was used [23]. A
standard serum was tested as a source of Bf, and functional
molecule titration was performed according to Kabat and
Mayer [211. The results of the titrations with polyacrilonitrile
(PAN)- and hydrate-incubated R-Bf were compared with that
obtained in control R-Bf (serum incubated alone).
Detection of granulocyte-aggregating activity
Detection of chemotactic factors in the patient plasma or in in
vitro activated plasma was performed by using granulocyte
aggregometry according to Hammerschmidt et al [20], with
minor modifications.
Peripheral blood from normal donors was collected in EDTA
20 mtvi. Theophylline (Sigma Chemical Company, St. Louis,
Missouri) was added to the blood to achieve a final concentra-
tion of 10 m. Red blood cell sedimentation was obtained by
adding equal volumes of ice-cold 3% dextran (Clinical Grade,
Sigma Chemical Company) in saline. Buffy-coat cells were
collected after 60 mm sedimentation at 4°C. Contaminating
erythrocytes were lysed by hypotonic shock. After restoration
of isotonicity, the suspension was centrifuged at x400g for 30
mm at 4°C on a Ficoll-Urovison gradient. Cells at the bottom
were recovered and adjusted to 15 x 106/ml with ice-cold final
buffer (isotonic saline, 0,5% albumin-theophylline 2.5 mM). The
resultant cell suspension was composed of greater than or equal
to 99% granulocytes (GC), as judged by May Grünwald-Giemsa
staining. Viability, assessed by trypan blue exclusion, always
exceeded 95%.
Granulocyte aggregometry was performed on a standard
platelet aggregometer (Elvi 840), by adding sequentially in the
cuvettes 200 jsl of the GC suspension, 20 d of 10 mivi Ca, 20
sl of 10 mivi Mg, and 20 pi of a 50 g/ml solution of
Cytochalasin B (Sigma Chemical Company). After adaptation
for 2 mm at 37°C, 20 Ll of the sample to be tested were added to
the stirred cell suspension. The aggregometer/recording system
was calibrated with a fresh GC suspension diluted 1:1 with final
buffer (100%), and the zT between the initial cell preparation
and 100% was set at 16 cm. Aggregation waves were recorded
as increments in light transmission on an arbitrary scale (zT).
In vitro plasma/serum incubation with dialyzer membranes
Normal plasma anticoagulated with 2 U/mI of heparin was
preincubated for 60 mm at 37°C in revolving plastic tubes
(Falcon 2001) with different dialyzer membranes at a ratio of 20
cm2 membrane/mi of plasma. Negative controls were fresh
plasma, plasma incubated alone, and decomplemented plasma
incubated with membranes. Positive control for plasma comple-
ment activation was provided by the use of Zymosan.
In a set of experiments, plasma was first incubated with
hydrate or PAN for 60 mm. At the end of the incubation period,
hydrate-incubated plasma was re-incubated with a new PAN
membrane, whereas PAN-incubated plasma was transferred on
a new hydrate membrane, and incubation was carried out for an
additional 60 mm. Moreover, normal serum was incubated with
hydrate or PAN in the presence of 20 mM EDTA, to prevent
complement activation. After a 60-mm incubation, serum was
removed and Ca and Mg concentration was restored. Sera
were tested in AP 50 assay, and comparisons were done
between membrane-incubated sera and the serum incubated
alone.
Removal of GC-aggregating activity by PAN
Normal serum activated by Zymosan was heated at 56°C to
prevent further possible complement activation by the mem-
branes and was subsequently incubated with PAN or hydrate
for 60 mm at 37°C. In a set of experiments, after the removal of
serum, PAN membrane was briefly washed with isotonic saline
and treated at room temperature for 60 mm with one of the
following: (1) distilled water; (2) NaCI 3 M; (3) glycine-HCI-
NaCI buffer pH 2.0. After recovery and reconstitution of
isotonicity and pH, the supernatants were tested for the ability
to induce GC aggregation.
In vitro "re-use" of hydrate membrane
In our Dialysis Unit, we do not re-use dialyzers routinely.
However, we tried to reproduce re-use of dialyzer membrane in
vitro by the following procedure. Hydrate membrane was
incubated with normal plasma as previously described. After
removal of plasma, the membrane was extensively washed with
isotonic saline and finally stored at room temperature with 3%
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Table 1. Arterial-blood neutrophil countsa in four groups of patients undergoing hemodialysis with different dialyzers
Dialyzer
Time of dialysis, mm
0 15 60 240
Hydrate
Cuprophan
Acetate
Polyacrilonitrile
3556
3224
3511
3431
380
361
344
268
301 60b
692 244h
1765 353°
3574 372
3241 398
2852 373
3557 358
4032 372
4400
3392
4200
3993
504
412
461
390
a Results are expressed as absolute numbers of circulating neutrophils/mm3. Mean values 5EM for each group of eight patients are given before
(time 0) and at different times of dialysis.
b P < 0.01
P < 0.05
Dialyzer
Complement
pathway
Time of dialysis, mm
15 60 240
Hydrate C
A
98 3
97±2
104 2
102±2
114
108±
4h
3b
Cuprophan C
A
86 5h
93±2h
97 3
101±4
114
113±
5b
5°
Acetate C
A
86 3b
96±Ib
101 2
103±3
123
122±
6b
5b
Polyacri-
lonitrile
C
A
90 2b
98 2
105 4
108 3°
123
115
7h
5°
formaldehyde in saline. After 48 hr the membrane was washed
and fresh plasma added again for 60 mm at 37°C. The entire
procedure was repeated three times, and plasma samples were
collected after each "re-use" for testing in GC aggregometry.
Two-dimensional immunoelectrophoresis of C3
Two-dimensional immunoelectrophoresis of C3 was per-
formed by standard techniques [24]. Anti-human C3 was pur-
chased from Behring Diagnostics, Morburg, West Germany.
'251-Clq binding by PAN membrane
Clq was purified from human serum [25] and radiolabelled
with 1251 by the lactoperoxidase method [26]. Radiolabelled Clq
(1 Ci/g, 1 g!ml in Veronal buffer pH 7.4) was incubated with
PAN and hydrate membranes for 60 mm at 37°C. At the end of
the incubation, the membranes were extensively washed and
counted in a gamma-counter. In inhibition experiments, PAN
was extensively adsorbed with normal serum (saturated PAN)
and, after washing, tested for the ability to bind '251-Clq. In
addition, '251-Clq binding was performed also in the presence
of excess "cold" Clq (100 tgIml).
Statistical analysis
Comparisons were made by the paired and unpaired Stu-
dent's t test. A P value of less than 0.05 was considered
Zymosan Hydrate Cuprophan Acetate PAN
Fig. 1. Effect on total hemolyuic complement activity of in Vitro
incubation of normal plasma with different dialyzer membranes and
Zymosan. Results are expressed as a percentage of values obtained in
the control (plasma incubated alone), and mean values SEM of six
consecutive experiments are depicted. Open columns represent CH 50
activity and closed columns AP 50 activity. All values are significant in
comparison with control (P < 0.01).
significant. Correlation coefficient was determined by linear
regression analysis.
Results
In vivo studies
Changes in circulating leukocytes in patients undergoing
hemodialysis. Table 1 shows the results of monitoring the
number of circulating GC at different times of dialysis. All the
dialyzers tested but PAN induced an early fall in neutrophil
counts, followed by a return to pre-dialysis levels after 4 hr
from the start of dialysis. At 15 mm, hydrate dialyzers were
most effective in provoking neutropenia (92% mean decrease),
followed by cuprophan (79% decrease), and cellulose acetate
(50% decrease) dialyzers.
Changes in complement activity in patients undergoing he-
modialysis. Hemolytic complement levels during hemodialysis
are shown in Table 2. At group level, a significant mean
decrease in both CH 50 and AP 50 activity was observed after
15 mm of dialysis with acetate and cuprophan membranes. On
the contrary, PAN dialyzers induced a significant reduction at
15 mm only via the classical pathway, whereas hydrate dialyz-
ers did not cause an early change.
However, the behavior of individual patients was extremely
different: The same type of dialyzer affected in some cases
Table 2. Changes in total hemolytic complement activitya in four
groups of eight patients undergoing hemodialysis with different
dialyzers
100
50
rL
I
I
0
0
>-
>
C.,
C.)
>-0
E
5)I
I
° Classical (C) and alternative (A) pathway activities are expressed as
a percentage of pre-dialysis values at different times of dialysis. Mean
values SEM for each group of patients are given.
b P < 0.01.
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Hydrate (l reuse)
Acetate Fig. 2. Generation of granulocyte-aggregating
activity by Zymosan and different dialyzer
membranes on in vitro incubation with human
plasma. One representative experiment is
shown. Arrows indicate addition of plasmas,
and increases in light transmission (AT) denote
aggregation of granulocytes stirred in the
aggregometer. A Negative and positive
controls, ZAP denotes Zymosan-activated
plasma. B The effect of plasmas activated with
different membranes.
either the classical or alternative pathway (or both), whereas in
some subjects no significant change in hemolytic complement
titer was detectable at all. However, no correlation was found
between the degree of complement depletion and neutropenia in
individual patients.
After 60 mm of dialysis, complement activity did not show
any significant difference in comparison with pre-dialysis val-
ues. At the end of the dialysis, a significant increase in serum
complement activity was evident in all the patients studied.
Such an increase, besides rebound hyperproduction, could be
related in part to the hemo-concentration occurring at the end of
dialysis.
When plasma samples were tested for the presence of circu-
lating GC-aggregating activity (GC-AA), no C5a-like activity
could be detected at any time of dialysis (not shown).
In vitro studies
Effect of dialyzer membranes on total hemolytic complement.
In vitro incubation of normal plasma with different dialyzer
membranes significantly affected total hemolytic complement
activity (Fig. 1). Complement depletion was more intense with
regard to the alternative pathway, particularly with hydrate and
PAN, but also cuprophan and acetate membranes were able to
induce a significant decrement of activity. As concerns the
classical pathway, complement depletion was less pronounced.
In six separate experiments, hydrate caused a mean decrement
of 30% and acetate a decrement of 25%, whereas cuprophan
and PAN provoked a reduction of activity of about 15%.
In vitro generation of GC-aggregating activity in normal
plasma by dialyzer membranes. In our experimental model
plasma incubated at 37°C for 60 mm induced a slight increase in
light transmission, owing to spontaneous complement decay
and chemotactic activity generation, whereas fresh plasma did
not induce any GC aggregation (Fig. 2A). When normal plasma
was incubated with dialyzer membranes, a sharp aggregation
wave was observed with all the membranes tested but PAN
(Fig. 2B). In six consecutive experiments, maximal GC-AA
generation occurred with hydrate (14.9 1.3 cm), but the
ability to generate such an activity was progressively lost on
sequential in vitro "re-use." Also, the cuprophan membrane
showed a strong generation of GC-AA (11.8 2.1 cm), whereas
cellulose acetate induced less pronounced, although still signifi-
cant, GC-AA generation (6.6 1.1 cm). On the other hand, GC
challenged with PAN-incubated plasma were still able to gener-
ate a sharp aggregation wave upon re-stimulation with hydrate-
incubated plasma (not shown).
Immunoelectrophoretic analysis of membrane-activated
plasma. Plasma incubated in vitro with hydrate and PAN
membranes was analyzed for C3 conversion. As shown in
Figure 3, a sizeable degree of C3 conversion was present also in
control plasma. More marked conversion, similar to the pattern
obtained in Zymosan-incubated plasma, was present in plasma
incubated with hydrate membrane. Surprisingly, the incubation
of plasma with PAN did not induce any increase in the C3c
peak. On the contrary, a striking reduction of both /31A(C3c)
and f3ic(C3) peaks, in comparison with control plasma, was
evident. Moreover, when Zymosan-activated serum was incu-
bated with PAN, a sharp reduction was observed in the
concentration of both C3 and C3c peaks, whereas the incuba-
tion with hydrate did not induce any significant change (not
shown).
Evidence for the adsorption of complement components by
PAN. To provide additional support for the hypothesis of an
adsorption of complement components by PAN, several experi-
mental approaches were undertaken. First of all, we showed
that incubation of plasma with PAN, but not with hydrate, even
in the presence of complement inhibitors (EDTA), completely
removed hemolytic activity. Analogously, when functional mol-
ecule titration was performed on a standard serum, the ability of
the serum depleted in factor B to act as a "finishing reagent"
was prevented by prior incubation with PAN but not with
hydrate (data not shown). These data were consistent with the
finding that pre-incubation of plasma with PAN prevented the
generation of GC-AA on subsequent contact with hydrate
membrane (not shown).
Additional evidence came from the finding that GC-AA was
removed completely from Zymosan-activated serum by incuba-
tion with PAN (Fig. 4). Any attempt to elute GC-AA from the
membrane by molar shock or acid buffer was ineffective.
Finally, direct evidence was provided by the adsorption of a
significant amount of '251-labelled Clq by PAN membrane (Fig.
5). The binding did not take place with PAN previously
incubated with normal serum or in the presence of excess
"cold" Clq molecules (not shown in the figure).
A BZAP
Plasma 37°CI-
Hydrate Inew)
Cuprophan
1 mm
111
Hydrate 12d reuse)
PAN
1111
Hemodialysis leukopenia and complement function 779
I-
1111
PAN-absorption
Eluate
Fig. 4. Effect of incubation with hydrate and polyacrilonitrile mem-
branes on the granulocyte-aggregating activity of Zymosan-acuiva ted
serum (ZAS). Absorption of ZAS with PAN membrane, but not with
hydrate, completely abrogated GC-aggregating activity. Subsequent
treatment of PAN with molar shock or acid buffer did not release any
GC-AA from the membrane (acid buffer eluate shown in the figure).
Fig. 3. Effect of in vitro incubation with hydrate and polyacrilonitrile
membranes on the two-dimensional immunoelectrophoretic pattern of
C3 of normal plasma. A strong increase in 131A peak, indicative of
massive C3 conversion, was evident in normal plasma incubated with
hydrate (B), whereas incubation with polyacrilonitrile (C) reduced both
J3 and /31A peaks, spontaneously present in plasma incubated alone(A). Arrows indicate the sense of electrophoretic migration.
Discussion
The results reported in this paper help to explain apparent
contradictions in the literature. Whereas the in vivo observa-
Fig. 5. Binding of '251-labelled Clq by polyacrilonitrile membrane. One
representative experiment is shown. The percentage of the radioactivity
absorbed onto the membrane/tube system (closed columns) in compari-
son with the total amount of cpm added (open columns) is depicted.
Binding by hydrate does not differ from that in the control tube,
whereas PAN adsorbs a sizeable amount of radiolabelled CIq. No
significant binding occurs on PAN previously incubated with normal
serum (saturated PAN).
ZAS
Hydrate-absorption
1 mm
C:
C.
C;)
0
C
C.)
cC-
Control Hydrate PAN < Saturated >
PAN
tions provide no clear answers, confirming contradictory re-
suits previously reported [16, 17], from in vitro investigations
two definite conclusions can be stated reasonably. The first one
is that the decrement in total hemolytic complement function
reported with PAN does not correspond to effective comple-
ment activation. The starting-point for this hypothesis was the
puzzling finding that the sharp complement depletion by PAN
observed in AP 50 test was not followed by in vitro chemotac tic
activity generation, as well as the fact that we could never show
an electrophoretic conversion of C3 during hemodialysis with
PAN dialyzers. To explain these findings, we considered the
possibility of an adsorption and/or inactivation of complement
components by PAN. We have developed a large body of
evidence, both functional and immunochemical, favoring this
hypothesis.
Obviously, it is beyond the limits of the present paper to
extensively investigate the mechanism(s) of the adsorption of
complement activity by PAN. We merely suggest that the
1A 1C
A
r
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E
I-
15
10
5
Fig. 6. Correlation between the ability of different membranes to
generate GC-aggregating activity upon in vitro incubation with normal
plasma and the degree of neutropenia induced by the corresponding
dialyzer. Mean increases in light transmission (ST) were calculated in
six consecutive experiments by testing the ability to generate GC-
aggregating activity of normal plasma incubated in vitro with hydrate
(LI), cuprophan (•), cellulose acetate (0), and polyacrilonitrile (•)
membranes. Mean zT SEM are plotted against the ability of the
relative dialyzer to induce neutropenia after 15 mm of hemodialysis,
expressed as mean percent decrease (± SEM) from the basal value in
eight individual patients (r = 0.993, P < 0.01).
phenomenon, especially keeping in mind the low concentration
of some complement components in the serum [271, could be
similar to that occurring with other related polymers, common-
ly used in radioimmunoassays, as polyvinyl and polystyrene.
The binding is very stable and, as in our experimental model,
any attempt to elute bound substances proves to be ineffective
(unpublished observation).
The second inference that we are able to draw from our
studies concerns the strict relationship between complement
system and hemodialysis leukopenia. In this paper, we demon-
strate that the problem of the role of the complement system in
hemodialysis-induced leukopenia should be thought of in terms
of the chemotactic factor generation by using a steady in vitro
model. In fact, when we plot the capability of in vitro genera-
tion of GC-AA by the different membranes versus the degree of
in vivo induced neutropenia, a striking correlation is evident
(Fig. 6). Additional evidence is afforded by the inability of re-
used" hydrate to generate GC-AA in vitro. In fact, it is known
that re-used dialyzers do not cause neutropenia [10, 181. Unfor-
tunately, due to difficulties in finding polycarbonate dialyzers in
Italy, we could not test this membrane. However, the relation-
ship between the in vitro GC-AA generation and the degree of
neutropenia induced by the membranes tested seems convinc-
ing enough, and the previously observed inability of polycar-
bonate dialyzers to cause a decrement of complement activity
likely resides in the low sensitivity of in vivo complement
studies. Actually, we feel that in vivo investigations are inade-
quate to the study of complement function during hemodialysis,
in that they simply reflect the balance between the rates of
consumption and de novo synthesis of complement compo-
nents, which can be extremely different in individual patients.
Neither the more sensitive technical approaches, as detection
of chemotactic factors and studies of C3 conversion (not
shown), afford definite conclusions. The inability to show
circulating GC-AA may result from dilution of the activated
components into the blood volume and/or rapid clearing of
chemotactic peptides from the circulation.
Although favoring the hypothesis of a pivotal role of chemo-
tactic factors in the pathogenesis of hemodialysis-induced leu-
kopenia, we do not exclude the possibility that other mecha-
nisms play a role. The finding that cuprophan membranes are
able to directly release from leukocytes cationic proteins,
substances known to be capable of mediating GC aggregation
[28, 291, as well as the finding that PAN dialyzers are able to
provoke a significant drop in arterial P02 (confirmed in many
laboratories including our own), seem to suggest that other
100 physiopathologic mechanisms could be involved [18].
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